DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Lumateperone
Lumateperone
Lumateperone Monograph
Atypical Antipsychotics TCO 02.2018
Lumateperone for Acute Exacerbations of Psychosis in Schizophrenia NIHRIO (HSRIC) ID: 10603 NICE ID: 9131
Lumateperone (Caplyta®) New Drug Update
APPROVED PA Criteria Page 1 of 4 Initial Approval
Currently Prescribed Psychotropic Medications
OTHER REVIEW(S) DEPARTMENT of HEALTH & HUMAN SERVICES Public Health Service
The Effectiveness of Lurasidone Add-On for Residual Aggressive
Caplyta (Lumateperone), an Atypical Antipsychotic Indicated for the Treatment of Schizophrenia in Adults
CAPLYTA® (Lumateperone)
Antipsychotic Medications Age and Step Therapy
Risk Assessment and Risk Mitigation Review(S)
Schizophrenia Treatment with Second-Generation Antipsychotics : a Multi-Country Comparison of the Costs of Cardiovascular and Metabolic Adverse Events and Weight Gain
Multi-Discipline Review
New Information of Dopaminergic Agents Based on Quantum Chemistry Calculations Guillermo Goode‑Romero1*, Ulrika Winnberg2, Laura Domínguez1, Ilich A
Intra-Cellular Therapies Announces Positive Topline Data from 6-Week Open-Label Safety Switching Study with Lumateperone in Patients with Schizophrenia
Lumateperone for Schizophrenia
Psychosis, Agitation, and Antipsychotic Drugs
Top View
A Phase 1 Exploratory Study in OLZ/SAM (P=0.015) but Not with Olanzapine Or Placebo
TMS Antidepressant Medication Record
CNS SPECTRUMS CME Review Article
Unitedhealthcare Community Plan of Arizona
Lumateperone) Capsules, for Oral Use (WBC) Or History of Leukopenia Or Neutropenia
Abilify Maintena, Aristada
Clinical Policy: Aripiprazole Long-Acting Injections (Abilify
Lumateperone (Caplyta®) FDA Approved December 2019 Intra-Cellular Therapies, Inc
New Treatments for Schizophrenia
Lumateperone (Caplyta) Reference Number: ERX.NPA.141 Effective Date: 03.01.20 Last Review Date: 02.21 Line of Business: Commercial, Medicaid Revision Log
Select Antipsychotics Step Therapy • Rexulti (Brexpiprazole)
Psychosis Treatments
A Clinically Oriented Review of Lurasidone, Brexpiprazole, Cariprazine and Lumateperone
Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention
Psychotropic Medications Consent Drug List (PDF)
Atypical Antipsychotics and Metabolic Syndrome: from Molecular Mechanisms to Clinical Differences
(Anthem) Hot Tip: Atypical Antipsychotics
Section I: Atypical Antipsychotics 12/2020
FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
Non-Preferred Drug List (NPDL)
Lumateperone
New Drug Evaluation Monograph Template
Psychotropic Drug Indications
Medicare Pharmacy Quality Alliance Medication
Optimizing Management of Schizophrenia (Rao)
Louisiana Medicaid Behavioral Health Medications for Children Under 6 Years of Age for Medications Not Addressed on the Preferred/Non-Preferred Drug List
Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: a Comprehensive Review
ITI-007): a Novel Investigational Agent with Broad Therapeutic Potential Across Multiple Neuropsychiatric Disorders